Advancements and challenges in CAR T cell therapy in autoimmune diseases
G Schett, F Müller, J Taubmann, A Mackensen… - Nature Reviews …, 2024 - nature.com
Chimeric antigen receptor (CAR) T cells are highly effective at targeting and eliminating cells
of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for …
of the B cell lineage. CAR T cell therapy has become a standard-of-care treatment for …
Advancing diagnostics and therapy to reach universal cure in childhood ALL
R Pieters, CG Mullighan, SP Hunger - Journal of Clinical Oncology, 2023 - ascopubs.org
Systemic combination chemotherapy and intrathecal chemotherapy markedly increased the
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …
survival rate of children with ALL. In the past two decades, the use of minimal (measurable) …
CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany
P Bader, C Rossig, M Hutter, FA Ayuk… - Blood …, 2023 - ashpublications.org
Patients with precursor B-cell acute lymphoblastic leukemia (pB-ALL) who have relapsed
after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more …
after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more …
CAR‐T cell therapy in hematological malignancies: Where are we now and where are we heading for?
AN Khan, S Asija, J Pendhari… - European Journal of …, 2024 - Wiley Online Library
Chimeric antigen receptor T (CAR‐T) therapy has emerged as a revolutionary new pillar in
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …
cancer care, particularly in relapsed/refractory (r/r) B‐cell malignancies. Following …
[HTML][HTML] Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma
K Rejeski, MD Jain, EL Smith - Transplantation and Cellular Therapy, 2023 - Elsevier
Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for …
Abstract Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD)
prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need to test …
prior to standard‐of‐care CAR T‐cell therapy for lymphoma. There is ongoing need to test …
Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy
K Rejeski, DM Cordas dos Santos, NH Parker… - Cancer Immunology …, 2023 - AACR
Although CD19-directed chimeric antigen receptor T-cell therapy (CD19. CAR-T) has proven
clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately …
clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately …
How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL
RM Myers, NN Shah, MA Pulsipher - Blood, 2023 - ashpublications.org
By overcoming chemotherapeutic resistance, chimeric antigen receptor (CAR) T cells
facilitate deep, complete remissions and offer the potential for long-term cure in a substantial …
facilitate deep, complete remissions and offer the potential for long-term cure in a substantial …
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
X Xiao, Y Wang, Z Zou, Y Yang, X Wang, X Xin… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the therapeutic
landscape of haematological malignancies. However, resistance and relapse remain …
landscape of haematological malignancies. However, resistance and relapse remain …
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Fludarabine is one of the most common agents given for lymphodepletion before CD19
chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data …
chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data …